FibroGen Inc. (NASDAQ:FGEN) traded up 4% during trading on Wednesday . The stock traded as high as $17.42 and last traded at $17.10, with a volume of 218,255 shares changing hands. The stock had previously closed at $16.44.

Several equities research analysts have recently commented on the stock. Zacks Investment Research downgraded shares of FibroGen from a “hold” rating to a “sell” rating in a research note on Tuesday, May 3rd. Credit Suisse Group AG restated a “buy” rating on shares of FibroGen in a research note on Wednesday, May 25th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. FibroGen presently has a consensus rating of “Buy” and an average target price of $33.50.

The company’s market cap is $1.06 billion. The stock has a 50-day moving average of $17.33 and a 200 day moving average of $19.75.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.11. Analysts forecast that FibroGen Inc. will post ($1.02) earnings per share for the current year.

In other FibroGen news, CEO Thomas B. Neff sold 13,500 shares of the stock in a transaction on Tuesday, April 19th. The stock was sold at an average price of $20.21, for a total transaction of $272,835.00. Following the transaction, the chief executive officer now owns 3,579,353 shares in the company, valued at approximately $72,338,724.13. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider K Peony Yu sold 2,344 shares of the stock in a transaction on Friday, June 10th. The stock was sold at an average price of $17.96, for a total value of $42,098.24. Following the transaction, the insider now owns 210,257 shares in the company, valued at approximately $3,776,215.72. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors have recently bought and sold shares of the company. Lebenthal Lisanti Capital Growth LLC boosted its position in FibroGen by 2.5% in the fourth quarter. Lebenthal Lisanti Capital Growth LLC now owns 35,668 shares of the biopharmaceutical company’s stock valued at $1,087,000 after buying an additional 863 shares during the last quarter. PNC Financial Services Group Inc. boosted its position in FibroGen by 8,621.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 35,756 shares of the biopharmaceutical company’s stock valued at $1,090,000 after buying an additional 35,346 shares during the last quarter. Tocqueville Asset Management L.P. boosted its position in FibroGen by 60.8% in the fourth quarter. Tocqueville Asset Management L.P. now owns 40,200 shares of the biopharmaceutical company’s stock valued at $1,214,000 after buying an additional 15,200 shares during the last quarter. Rhumbline Advisers boosted its position in FibroGen by 8.7% in the fourth quarter. Rhumbline Advisers now owns 45,940 shares of the biopharmaceutical company’s stock valued at $1,400,000 after buying an additional 3,675 shares during the last quarter. Finally, Nationwide Fund Advisors boosted its position in FibroGen by 0.8% in the fourth quarter. Nationwide Fund Advisors now owns 51,597 shares of the biopharmaceutical company’s stock valued at $1,572,000 after buying an additional 393 shares during the last quarter.

FibroGen, Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.